Ocular surface disease associated with immune checkpoint inhibitor therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ocular surface disease associated with immune checkpoint inhibitor therapy
Authors
Keywords
Ocular surface disease, Dry eye disease, Immune checkpoint inhibitor, Immune related adverse event, Keratitis, Conjunctivitis, Ocular rosacea, T cell
Journal
Ocular Surface
Volume 20, Issue -, Pages 115-129
Publisher
Elsevier BV
Online
2021-02-21
DOI
10.1016/j.jtos.2021.02.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
- (2020) Xiaowei Liu et al. Thoracic Cancer
- Bilateral Corneal Graft Rejection Associated With Pembrolizumab Treatment
- (2020) Eva Vanhonsebrouck et al. CORNEA
- Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors
- (2020) Junko Hori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The impact of anticancer drugs on the ocular surface
- (2020) Jeremy Chung Bo Chiang et al. Ocular Surface
- Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
- (2020) Blake Hugo Fortes et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy
- (2020) Anaïs Ramaekers et al. CORNEA
- Immune checkpoint inhibitors and corneal transplant rejection: a call for awareness
- (2020) Harpal Singh Sandhu et al. Immunotherapy
- Autoimmune Keratitis after Atezolizumab Treatment
- (2020) Joo Youn Oh NEW ENGLAND JOURNAL OF MEDICINE
- Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series
- (2019) Jenna May Kim et al. OPHTHALMOLOGY
- Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy
- (2019) Karen Bitton et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies
- (2019) Carl W. Noble et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies
- (2019) Seungwon An et al. Ocular Surface
- Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
- (2019) Blake M. Warner et al. ONCOLOGIST
- Immune privilege in corneal transplantation
- (2019) Junko Hori et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease
- (2019) Jieun Kwon et al. Ocular Surface
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
- (2018) Chia-Chieh Hsiao et al. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients
- (2018) Oded Sagiv et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Innate and Adaptive Cell Populations Driving Inflammation in Dry Eye Disease
- (2018) José L. Reyes et al. MEDIATORS OF INFLAMMATION
- Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review
- (2017) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- TFOS DEWS II Epidemiology Report
- (2017) Fiona Stapleton et al. Ocular Surface
- Review of cancer treatment with immune checkpoint inhibitors
- (2017) Christiane Thallinger et al. WIENER KLINISCHE WOCHENSCHRIFT
- Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions
- (2017) Chen Fu et al. Oncotarget
- Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology
- (2017) Mary Elizabeth Davis et al. Seminars in Oncology Nursing
- Ocular and orbital side-effects of checkpoint inhibitors
- (2016) Joëlle Antoun et al. CURRENT OPINION IN ONCOLOGY
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Corneal graft rejection in a patient treated with nivolumab for primary lung cancer
- (2016) S. Le Fournis et al. LUNG CANCER
- Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
- (2016) J. Weber et al. Cancer Immunology Research
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab
- (2015) Amanda D. Henderson et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
- (2014) G. T. Gibney et al. CLINICAL CANCER RESEARCH
- Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
- (2014) Kent Shih et al. DRUGS
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Dry Eye Disease
- (2012) William Stevenson ARCHIVES OF OPHTHALMOLOGY
- Anti–Cytotoxic T-Cell Lymphocyte Antigen-4–Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss
- (2012) Caroline Voskens et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease
- (2012) Stefano Barabino et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- Autoimmunity at the ocular surface: pathogenesis and regulation
- (2010) M E Stern et al. Mucosal Immunology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now